Dermatology News and Research

Latest Dermatology News and Research

Roche conducts third Phase 1 clinical trial utilizing Halozyme’s Enhanze Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that the first patient was dosed in a Phase 1 pharmacokinetic clinical trial using Enhanze™ Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.

10 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Karolinska Development announces formation of Pergamum AB business unit

Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

10 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

Neuroprosthetics 2009 national conference to focus on artificial limbs

On September 16, leaders in research and development of implantable limb neuroprosthetics will gather at Worcester Polytechnic Institute (WPI) to discuss the state of the field and to advance collaborations that will push next-generation artificial limbs and prosthetic devices closer to clinical application.

9 Sep 2009

Moisturizing skin helps manage Keratosis Pilaris

KP is a genetic skin condition that affects 40 percent of the world's population, often resulting in patches of dry skin, and little red bumps, on the arms and legs. KP is most prevalent in the teenage years but may continue throughout adulthood. There is no cure for Keratosis Pilaris.

9 Sep 2009

Can-Fite's Phase II clinical study of CF101 provides positive results

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today that its 75-patient Phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.

9 Sep 2009

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.

8 Sep 2009

Regurin XL capsule for the treatment of OAB launched in UK

Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R) XL provides rapid, significant and consistent improvements in the symptoms of OAB1 and has a reduced potential for central nervous system (CNS) side effects(2-7).

7 Sep 2009

Fashion show to help raise public awareness of psoriasis

Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City.

3 Sep 2009

Peplin announces merger agreement with LEO Pharma

Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash. This represents a purchase price of US$16.99 per common share of Peplin stock or A$1.03 per Peplin CHESS Depositary Interest (CDI).

3 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

Ferguson, the founding professional agency of CommonHealth, today announced the launch of the Ferguson OTC (over-the-counter) Center of Excellence, a new initiative designed to address the rapid increase of promotion and use of OTC drugs.

2 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

NF-kappa B inhibitors protect against toxicity during radiation treatment

Directly inhibiting the activity of a key protein mediator of inflammation reduced radiation toxicity in zebrafish embryos, and may ultimately be of help to patients receiving radiation therapy, according to researchers from the Kimmel Cancer Center at Jefferson.

2 Sep 2009

AAD urges Americans to remind grandparents to perform skin self-examination

Sunday, September 13, is National Grandparents Day, and the American Academy of Dermatology (Academy) recommends that people lovingly remind their grandparents to perform a skin self-examination.

1 Sep 2009

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009